Aligos Therapeutics ALGS Cash Flow Statement (2019-2026)

NASDAQ ALGS
$5.33 -0.17 (-3.09%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Aligos Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

Aligos Therapeutics reported cash from operations of -$24.95M and free cash flow of -$24.95M for the quarter ended Jun 2026, down 60.9% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-33.12M-37.71M-35.62M-19.92M-18.62M-21.89M-22.95M-18.79M-18.04M-27.89M-34.86M5.06M-19.26M-82.15M43.09M-15.86M-31.54M-14.55M-23.04M-1.50M
Share-based CompensationStock Comp.
5.64M3.65M9.24M9.01M10.08M3.42M10.79M10.51M11.13M2.58M10.13M10.04M2.04M1.71M1.01M1.16M1.68M1.46M2.11M2.14M
Gains from Investment SecuritiesGains Investment
14.37M-30.48M0.10M62.13M-61.49M-1.68M4.21M-1.21M-3.40M-2.98M
Asset Writedowns and ImpairmentWritedown
0.70M
Cash from OperationsCash from Ops.
-25.37M-37.48M-20.43M-25.04M-17.14M-16.78M-22.39M-13.62M-20.34M-22.66M-22.75M-19.49M-20.10M-18.40M-20.91M-15.50M-24.34M-21.75M-23.13M-24.95M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.19M0.28M0.31M0.32M0.37M0.38M0.39M0.36M0.37M0.38M0.39M0.54M0.47M0.37M0.32M0.72M0.71M0.44M0.51M0.47M
Change in Working Capital
Change in Account PayablesChange Payables
1.12M0.40M0.74M-0.99M0.17M1.81M-1.92M0.42M-0.30M-0.42M0.33M3.98M-4.08M-0.17M1.73M-0.40M0.75M-0.67M3.66M-1.21M
Change in Accured ExpensesChange Accured Exp.
4.00M3.88M-6.07M-6.35M0.90M2.39M-0.94M-1.26M-1.46M4.58M-4.80M0.02M2.10M1.29M-4.76M1.41M1.40M-0.08M-1.54M6.71M
Other Working Capital ChangesOther WC Changes
-1.54M12.06M-3.62M-1.98M-0.57M0.57M-2.09M-2.17M0.78M1.18M-0.20M-0.14M-0.17M0.30M0.15M-0.34M-0.59M0.68M-0.32M-0.62M
Investing Activities
Capital ExpendituresCapex
0.10M0.34M0.52M0.33M0.00M0.09M0.01M
Change in Acquisitions & DivestmentsChange Acquisitions
3.00M10.00M37.45M36.22M20.00M25.00M0.01M30.00M20.00M20.00M70.00M37.50M35.00M25.00M
Cash from Investing ActivitiesCash from Investing
-0.04M-16.48M-60.40M-9.98M32.48M11.60M19.99M25.00M-0.01M-0.01M-88.64M39.99M10.40M19.97M-44.07M-39.42M47.68M-2.02M34.93M25.00M
Financing Activities
Other financing activitiesOther financing
0.02M0.01M0.10M0.09M0.02M0.44M0.09M0.14M0.12M
Cash from Financing ActivitiesCash from Financing
77.95M0.55M-0.02M0.08M-0.02M0.12M-0.00M0.41M-0.02M87.94M-0.02M0.28M-0.00M0.10M101.74M-0.18M-0.05M0.12M-0.06M0.22M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
0.48M3.64M5.09M1.52M2.25M2.89M0.36M0.41M1.16M0.44M
Additional items
Change in Cash
52.54M-53.41M-80.86M-34.93M15.33M-5.06M-2.40M11.80M-20.37M65.27M-111.41M20.78M-9.71M1.67M36.77M-55.10M23.29M-23.64M11.74M0.27M
Free Cash FlowFCF
-25.46M-37.82M-20.95M-25.37M-17.14M-16.87M-22.39M-13.62M-20.34M-22.66M-22.75M-19.49M-20.10M-18.40M-20.91M-15.50M-24.34M-21.75M-23.13M-24.95M
Net Cash FlowNCF
52.54M-53.41M-80.86M-34.93M15.33M-5.06M-2.40M11.80M-20.37M65.27M-111.41M20.78M-9.71M1.67M36.77M-55.10M23.29M-23.64M11.74M0.27M